License agreement between Theranexus and Exeltis for TX01

Theranexus and Exeltis, a subsidiary of Insud Pharma Group, announce a licensing agreement for the commercialization of the TX01 formulation. This treatment targets two rare neurological diseases, Gaucher disease and Niemann-Pick disease type C. Exeltis will obtain exclusive commercialization rights in key regions, including the European Union and Latin America.

Theranexus will receive an upfront payment of €2 million, along with milestone payments and double-digit royalties on net sales. This partnership leverages Theranexus’ expertise in drug development and Exeltis’ ability to effectively commercialize on the global market.